Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.54 |
| ▸ | BID | P55957 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.50 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28193718 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003626 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1002751 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1004554 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1002777 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL421013 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1004461 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL5566506 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003944 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003237 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313841-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. | 2025-10-09 | — | — | US | disclosed |
| US-12312586-B2 | Treatment of MST1 related diseases and disorders | EMPIRICO INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250043281-A1 | TREATMENT OF FGG RELATED DISEASES AND DISORDERS | EMPIRICO INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240392296-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240287519-A1 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. | 2024-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043281-A1 | TREATMENT OF FGG RELATED DISEASES AND DISORDERS | FGR, PYGB, FBL | LMNA 3504/4885MEN1 3183/4885NR1I2 1440/4885 |
| US-20240392296-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | MST1, MSTN, MST1R | LMNA 1666/4885MEN1 1605/4885NR1I2 3042/4885 |
| US-12312586-B2 | Treatment of MST1 related diseases and disorders | MST1, MSTN, MST1R | LMNA 1666/4885MEN1 1605/4885NR1I2 3042/4885 |
| US-20250313841-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | MST1, MSTN, MST1R | LMNA 1666/4885MEN1 1605/4885NR1I2 3042/4885 |
| US-20240287519-A1 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | DKK1, EYA2, DKC1 | LMNA 2384/4885MEN1 2396/4885NR1I2 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.